Dai, C., Dehm, S. M. & Sharifi, N. Targeting the androgen signaling axis in prostate cancer. J. Clin. Oncol. 41, 4267–4278 (2023).

Article  CAS  Google Scholar 

Sharifi, N. Minireview: androgen metabolism in castration-resistant prostate cancer. Mol. Endocrinol. 27, 708–714 (2013).

Article  CAS  PubMed  Google Scholar 

Dai, C. et al. Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues. Clin. Cancer Res. 23, 6351–6362 (2017).

Article  CAS  PubMed  Google Scholar 

Chang, K.-H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728–13733 (2011).

Article  CAS  Google Scholar 

Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447–4454 (2008).

Article  CAS  PubMed  Google Scholar 

Geller, J. et al. DHT concentrations in human prostate cancer tissue. J. Clin. Endocrinol. Metab. 46, 440–444 (1978).

Article  CAS  Google Scholar 

Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11, 4653–4657 (2005).

Article  CAS  PubMed  Google Scholar 

Auchus, R. J. & Sharifi, N. Sex hormones and prostate cancer. Annu. Rev. Med. 71, 33–45 (2020).

Article  CAS  Google Scholar 

Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34–45 (2001).

Article  CAS  PubMed  Google Scholar 

Hettel, D. & Sharifi, N. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer. Nat. Rev. Urol. 15, 191–196 (2018).

Article  CAS  PubMed  Google Scholar 

Hussain, M. et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 10, 807–820 (2024).

Article  PubMed  Google Scholar 

Sabharwal, N. & Sharifi, N. HSD3B1 genotypes conferring adrenal-restrictive and adrenal-permissive phenotypes in prostate cancer and beyond. Endocrinology 160, 2180–2188 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428–11436 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simard, J. et al. Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family. Endocr. Rev. 26, 525–582 (2005).

Article  CAS  Google Scholar 

Evaul, K., Li, R., Papari-Zareei, M., Auchus, R. J. & Sharifi, N. 3β-Hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151, 3514–3520 (2010).

Article  CAS  Google Scholar 

Chang, K. H. et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154, 1074–1084 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hearn, J. W. D. et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 17, 1435–1444 (2016).

Article  CAS  PubMed  Google Scholar 

Locke, J. A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407–6415 (2008).

Article  CAS  Google Scholar 

Thomas, L. & Sharifi, N. Germline HSD3B1 genetics and prostate cancer outcomes. Urology 145, 13–21 (2020).

Article  PubMed  Google Scholar 

Chang, K., Ercole, C. & Sharifi, N. Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. Br. J. Cancer 111, 1249–1254 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hahn, A. W. et al. Germline variant in HSD3B1 (1245 A > C) and response to abiraterone acetate plus prednisone in men with new-onset metastatic castration-resistant prostate cancer. Clin. Genitourin. Cancer 16, 288–292 (2018).

Article  PubMed  Google Scholar 

Shiota, M. et al. Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone. JAMA Netw. Open 2, e190115 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Khalaf, D. J. et al. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Ann. Oncol. 31, 1186–1197 (2020).

Article  CAS  Google Scholar 

Sharifi, N. Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean? Ann. Oncol. 31, 1103–1105 (2020).

Article  PubMed  Google Scholar 

Varenhorst, E. et al. Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. Cancer Med. 5, 407–414 (2016).

Article  CAS  Google Scholar 

Agarwal, N. et al. Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer. JAMA Oncol. 3, 856–857 (2017).

Article  PubMed Central  Google Scholar 

Wu, G. et al. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer. Prostate 75, 777–782 (2015).

Article  CAS  PubMed  Google Scholar 

Borrell, L. N. et al. Race and genetic ancestry in medicine — a time for reckoning with racism. N. Engl. J. Med. 384, 474–480 (2021).

Article  Google Scholar 

Hougen, H. Y. et al. Disparities in diagnosis, treatment access, and time to treatment among Hispanic men with metastatic prostate cancer. JCO Oncol. Pract. 19, 645–653 (2023).

Article  PubMed  Google Scholar 

Moul, J. W. Real-world analyses of mortality risk after androgen deprivation therapy initiation in Black vs. White patients with prostate cancer. J. Clin. Oncol. 42, 84–84 (2024).

Article  Google Scholar 

Morgan, K. M. et al. Androgen deprivation therapy and outcomes after radiation therapy in black patients with prostate cancer. JAMA Netw. Open 7, e2415911 (2024).

Article  PubMed  Google Scholar 

Hearn, J. W. D. et al. Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer. JAMA Oncol. 4, 558–562 (2018).

Article  PubMed  Google Scholar 

de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

Article  PubMed  Google Scholar 

Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2012).

Article  PubMed Central  Google Scholar 

Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

Article  CAS